Despite facing substantial headwinds, Pfizer's strategic pivot away from pandemic-related products is showing early signs of success. The company's second-quarter 2025 results revealed a 10% year-over ...

GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.

Two new real-world studies estimate the effectiveness of a single dose of a respiratory syncytial virus (RSV) vaccine against ...

Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion. Click here to find out why PFE stock is a Buy.

CINEHEALTH International Health and Wellness Film and Video Festival took place in conjunction with the Fierce Pharma Marketing Awards ...

The FDA approved 2025-2026 COVID vaccines from Pfizer (Comirnaty), Moderna (Spikevax, mNexspike), and Novavax (Nuvaxovid), the companies announced on Wednesday. But the agency removed one of the ...

Pfizer Inc.'s strong Q2 2025 sales defy expectations. Discover analyst insights, growth drivers, and why it's rated Strong ...

Pfizer's strong Q2 results, high dividend yield, and bullish chart fuel optimism despite patent losses and rising competition ...

Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY), two pharmaceutical giants, are excellent examples. These stocks aren ...

A new multi-state study, which included Vanderbilt University Medical Center, shows that one RSV vaccine can protect older adults for two seasons.

Respiratory syncytial virus (RSV) vaccination packed a protective punch that lasted beyond a single season and extended to ...

Sept 3 (Reuters) - Pfizer (PFE.N), opens new tab and Moderna (MRNA.O), opens new tab on Wednesday defended their COVID-19 vaccines as having saved millions of lives worldwide, in separate responses to ...